GlassScriptPhysician profile
Manuel Mendez
NPI 1124471156
$3,408.26
in general payments reported to CMS, 2019-2025
23 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.38 · 2023: $233 · 2024: $1,686 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287 · Education: $97.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.56 |
| Education | $97.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $959.18 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $493.06 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $284.55 | 2023-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $225.94 | 2023-2025 | Dupixent |
| Mylan Specialty L.P. | $204.90 | 2023-2024 | Yupelri |
| Genzyme Corporation | $190.52 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.70 | 2024-2025 | Ofev, Jascayd |
| Amgen INC. | $143.23 | 2024-2025 | Tezspire |
| Philips North America LLC | $127.94 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Asahi Intecc USA, INC. | $100.00 | 2024 | Peripheral Vascular |
| Harmony Biosciences LLC | $83.49 | 2024-2025 | |
| Pfizer INC. | $75.29 | 2020-2024 | |
| United Therapeutics Corporation | $65.94 | 2024-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $49.88 | 2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $42.39 | 2025 | Lumryz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $39.64 | 2025 | Yupelri |
| Verona Pharma, INC. | $37.77 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $24.38 | 2025 | Keytruda |
| Inspire Medical Systems, INC. | $22.16 | 2024 | Inspire |
| Exact Sciences Corporation | $21.82 | 2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $21.77 | 2025 | |
| Grifols USA, LLC | $20.11 | 2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $15.60 | 2025 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.